Related Experiment Videos
[Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone]
J L Pouly1, S Bassil, R Frydman
1Département de Gynécologie Obstétrique et Reproduction, l'Hôtel Dieu, CHU 63003.
Contraception, Fertilite, Sexualite (1992)
|July 1, 1997
Summary
Vaginal progesterone (Crinone) and oral progesterone (Utrogestan) showed similar efficacy for in vitro fertilisation (IVF) luteal phase support. Crinone had fewer side effects like drowsiness, highlighting the transvaginal route
Area of Science:
- Reproductive Endocrinology
- In Vitro Fertilisation (IVF)
Background:
- Luteal phase support is crucial for IVF success.
- Progesterone administration routes vary, impacting efficacy and safety.
Purpose of the Study:
- To compare the efficacy and safety of vaginal progesterone (Crinone) versus oral progesterone (Utrogestan) for luteal phase support in IVF patients.
Main Methods:
- Randomized trial of 283 patients undergoing IVF.
- Comparison of 90 mg/day vaginal Crinone versus 300 mg/day oral Utrogestan.
- Treatment initiated post-embryo transfer and continued until day 30 if implantation occurred.
Main Results:
- No significant differences in pregnancy rates at days 12, 30, or 90 between Crinone and Utrogestan groups.
- Similar delivery rates and live birth ratios per transferred embryo.
- Vaginal progesterone (Crinone) showed significantly less drowsiness compared to oral progesterone (Utrogestan).
Conclusions:
- Vaginal progesterone (Crinone) is as effective as oral progesterone (Utrogestan) for IVF luteal phase support.
- The transvaginal route may offer a safety advantage by avoiding first-pass liver metabolism.
- Both formulations demonstrated comparable safety profiles, with drowsiness being the main differentiator.